Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
https://x.com/JenniferJJacobs/status/1986518429478568383
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4.25 to $4.
GoodRx Holdings (NASDAQ:GDRX) FY2025 Revenue expected to be more than $792.300M vs $797.952M Est
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0....
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug cost...
The all-in-one solution includes a virtual consultation, clinically proven prescription medication, and discreet home delivery,...
https://www.hy-vee.com/corporate/news-events/news-press-releases/hyvee-pharmacy-patients-can-now-purchase-ozempic--wegovy-at-a-...
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.
